ERBB2 and neoplasm: These results, together with our data showing that T-DXd is similarly effective in patients treated in first/second versus more advanced treatment lines, suggests that HER2+ mBC sensitivity to T-DXd is not significantly affected by the number of prior lines of anti-HER2 therapies, but it could reflect intrinsic tumor sensitivity or resistance to this agent.